Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Monique Spillman

Concepts (262)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Ovarian Neoplasms
17
2023
450
1.920
Why?
Endometrial Neoplasms
5
2015
137
0.880
Why?
Gynecology
5
2020
49
0.840
Why?
Genital Neoplasms, Female
2
2020
41
0.780
Why?
Gene Expression Regulation, Neoplastic
10
2019
824
0.770
Why?
Cystadenocarcinoma, Serous
4
2021
71
0.730
Why?
Infection Control
1
2020
47
0.690
Why?
Ethics, Medical
1
2020
45
0.680
Why?
Communication
1
2020
247
0.610
Why?
Conflict of Interest
3
2016
25
0.610
Why?
Uterus
1
2018
87
0.590
Why?
Medical Oncology
3
2020
95
0.590
Why?
Robotics
2
2014
41
0.570
Why?
Pneumonia, Viral
1
2020
170
0.560
Why?
Peptides
3
2015
220
0.560
Why?
Coronavirus Infections
1
2020
179
0.550
Why?
Receptors, Estrogen
5
2017
130
0.550
Why?
Medroxyprogesterone Acetate
1
2015
6
0.530
Why?
Fallopian Tube Neoplasms
2
2013
14
0.530
Why?
Antineoplastic Agents, Hormonal
1
2015
49
0.500
Why?
Pandemics
1
2020
566
0.500
Why?
Glycoproteins
1
2015
115
0.500
Why?
Gynecologic Surgical Procedures
2
2014
28
0.490
Why?
Neoplastic Stem Cells
1
2015
100
0.480
Why?
Antigens, CD
1
2015
215
0.470
Why?
Adenocarcinoma
2
2015
401
0.470
Why?
Female
34
2023
26571
0.440
Why?
Salpingectomy
1
2013
6
0.430
Why?
MicroRNAs
4
2021
347
0.430
Why?
Peritoneal Neoplasms
2
2011
61
0.430
Why?
Pelvic Neoplasms
1
2013
14
0.430
Why?
General Surgery
1
2014
106
0.420
Why?
Estrogens
2
2012
222
0.410
Why?
Clinical Trials as Topic
2
2007
466
0.390
Why?
Medicare Part B
1
2011
5
0.390
Why?
Professional Corporations
1
2011
1
0.390
Why?
Marketing of Health Services
1
2011
7
0.390
Why?
Reimbursement Mechanisms
1
2011
22
0.390
Why?
Physicians
2
2016
229
0.380
Why?
Social Responsibility
1
2011
26
0.380
Why?
Receptors, Progesterone
4
2015
63
0.380
Why?
Cell Line, Tumor
11
2016
1388
0.380
Why?
Trust
1
2011
61
0.370
Why?
Humans
42
2023
49922
0.370
Why?
Carcinoma, Large Cell
1
2010
15
0.360
Why?
Carcinoma, Neuroendocrine
1
2010
23
0.360
Why?
Interprofessional Relations
1
2011
85
0.360
Why?
Health Care Reform
1
2010
22
0.360
Why?
Physician-Patient Relations
1
2011
143
0.350
Why?
Breast Neoplasms
4
2012
1183
0.330
Why?
Uterine Neoplasms
2
2019
60
0.310
Why?
Transplantation, Heterologous
2
2012
75
0.300
Why?
Uterine Cervical Neoplasms
1
2010
276
0.300
Why?
Physician's Role
2
2011
48
0.290
Why?
MAP Kinase Kinase 4
1
2007
29
0.280
Why?
Apoptosis
5
2016
1092
0.280
Why?
Genes, Tumor Suppressor
1
2007
73
0.280
Why?
Advance Directives
1
2007
29
0.280
Why?
Patient Dropouts
1
2007
51
0.270
Why?
Gene Expression Regulation, Enzymologic
1
2007
178
0.260
Why?
Receptors, Transforming Growth Factor beta
1
2005
25
0.250
Why?
Claudin-4
2
2016
7
0.250
Why?
Antineoplastic Combined Chemotherapy Protocols
1
2010
994
0.240
Why?
Ovary
1
2004
114
0.230
Why?
Hysterectomy
2
2014
88
0.230
Why?
Epithelial Cells
1
2004
209
0.210
Why?
Reverse Transcriptase Polymerase Chain Reaction
2
2017
579
0.210
Why?
Aged
11
2021
9448
0.210
Why?
Middle Aged
12
2021
12289
0.200
Why?
Neoplasm Staging
4
2021
749
0.200
Why?
Gene Expression Profiling
3
2019
1028
0.200
Why?
Cisplatin
2
2015
275
0.190
Why?
Cell Movement
3
2016
245
0.180
Why?
Immunohistochemistry
6
2017
972
0.180
Why?
Resource Allocation
1
2020
16
0.180
Why?
Standard of Care
1
2020
17
0.180
Why?
Disclosure
2
2016
38
0.180
Why?
Loss of Heterozygosity
2
2013
77
0.180
Why?
Lymphatic Metastasis
2
2010
226
0.170
Why?
Early Detection of Cancer
1
2021
163
0.170
Why?
Leiomyosarcoma
1
2019
23
0.170
Why?
Leiomyoma
1
2019
25
0.170
Why?
Neoplasm Invasiveness
3
2015
268
0.160
Why?
Xenograft Model Antitumor Assays
4
2012
212
0.160
Why?
RNA-Binding Proteins
2
2019
120
0.160
Why?
Informed Consent
3
2004
97
0.160
Why?
Death
1
2018
21
0.150
Why?
Living Donors
1
2018
23
0.150
Why?
Critical Care
1
2020
214
0.150
Why?
Neoplasms, Glandular and Epithelial
2
2015
41
0.150
Why?
Palliative Care
1
2020
185
0.150
Why?
Carcinosarcoma
1
2017
18
0.150
Why?
Microfilament Proteins
1
2017
42
0.150
Why?
Sequence Analysis, RNA
1
2017
88
0.140
Why?
United States
4
2016
4880
0.140
Why?
Adult
7
2021
13355
0.140
Why?
Mice, Nude
3
2012
252
0.130
Why?
Industry
1
2016
17
0.130
Why?
Keratin-5
1
2015
2
0.130
Why?
Carrier Proteins
1
2017
302
0.130
Why?
Receptors, Androgen
1
2015
46
0.130
Why?
Cell Count
1
2015
147
0.130
Why?
Prognosis
4
2017
1956
0.130
Why?
Cell Proliferation
4
2015
986
0.130
Why?
Neoplasm Seeding
1
2014
4
0.120
Why?
Genetic Privacy
2
2004
3
0.120
Why?
Alanine
1
2014
41
0.120
Why?
Triazines
1
2014
24
0.120
Why?
Endometrium
1
2014
40
0.110
Why?
Genes, BRCA2
1
2013
12
0.110
Why?
Genes, BRCA1
1
2013
19
0.110
Why?
Mice
6
2016
5658
0.110
Why?
Insurance, Health, Reimbursement
1
2013
24
0.110
Why?
Health Care Costs
2
2013
168
0.110
Why?
Neoplasms, Cystic, Mucinous, and Serous
1
2012
7
0.110
Why?
DNA Methylation
3
2023
544
0.110
Why?
Risk Reduction Behavior
1
2013
58
0.100
Why?
Carcinoma, Lobular
1
2012
33
0.100
Why?
DNA-Binding Proteins
2
2013
424
0.100
Why?
Paclitaxel
1
2012
83
0.100
Why?
Lymph Nodes
1
2014
257
0.100
Why?
Antibodies, Neoplasm
1
2012
28
0.100
Why?
Coercion
1
2011
6
0.100
Why?
Judicial Role
1
2011
6
0.100
Why?
Medicare Payment Advisory Commission
1
2011
2
0.100
Why?
Personal Autonomy
1
2011
15
0.100
Why?
Women
1
2011
29
0.100
Why?
Prejudice
1
2011
40
0.100
Why?
Politics
1
2011
25
0.100
Why?
Homeodomain Proteins
1
2012
83
0.100
Why?
Quality of Health Care
1
2013
184
0.100
Why?
Violence
1
2011
61
0.090
Why?
M Phase Cell Cycle Checkpoints
1
2011
4
0.090
Why?
Taxoids
1
2011
37
0.090
Why?
Selective Estrogen Receptor Modulators
1
2010
23
0.090
Why?
RNA, Messenger
2
2012
1099
0.090
Why?
Organ Specificity
1
2010
106
0.090
Why?
Immunoenzyme Techniques
1
2010
141
0.090
Why?
Obstetrics
1
2011
86
0.090
Why?
Models, Statistical
1
2011
225
0.090
Why?
Cesarean Section
1
2011
159
0.090
Why?
Neoplasm Recurrence, Local
1
2014
626
0.090
Why?
Alcohol Drinking
1
2011
221
0.090
Why?
Societies, Medical
1
2010
177
0.080
Why?
Blotting, Western
1
2010
587
0.080
Why?
Oligonucleotide Array Sequence Analysis
1
2010
409
0.080
Why?
Transfection
2
2012
354
0.080
Why?
Phosphorylation
2
2008
526
0.080
Why?
Animals
6
2016
13100
0.080
Why?
Aging
1
2013
669
0.080
Why?
Aged, 80 and over
4
2021
3137
0.080
Why?
Alleles
2
2006
251
0.070
Why?
Case-Control Studies
2
2014
1128
0.070
Why?
Antineoplastic Agents
1
2015
1175
0.070
Why?
Chimera
1
2007
9
0.070
Why?
CpG Islands
1
2007
106
0.070
Why?
MAP Kinase Signaling System
1
2007
118
0.070
Why?
Genomic Imprinting
1
2006
10
0.070
Why?
Insulin-Like Growth Factor II
1
2006
19
0.070
Why?
RNA, Untranslated
1
2006
14
0.070
Why?
Health Services Accessibility
1
2010
417
0.070
Why?
Base Sequence
1
2007
657
0.060
Why?
Repetitive Sequences, Amino Acid
1
2005
1
0.060
Why?
Molecular Sequence Data
1
2007
799
0.060
Why?
Models, Biological
2
2008
719
0.060
Why?
North Carolina
1
2005
53
0.060
Why?
Databases, Nucleic Acid
1
2004
12
0.060
Why?
Telomerase
1
2004
26
0.060
Why?
Carcinoma
1
2006
139
0.060
Why?
Promoter Regions, Genetic
1
2007
467
0.060
Why?
Polymorphism, Genetic
1
2005
181
0.060
Why?
RNA Interference
2
2016
178
0.060
Why?
RNA, Small Interfering
2
2016
210
0.060
Why?
Tumor Burden
2
2016
131
0.060
Why?
Cell Survival
2
2016
590
0.060
Why?
Family Health
1
2004
79
0.060
Why?
Genetic Counseling
1
2004
40
0.060
Why?
Epigenesis, Genetic
1
2006
370
0.050
Why?
Genomics
1
2004
284
0.050
Why?
Researcher-Subject Relations
1
2002
1
0.050
Why?
Ethical Review
1
2002
2
0.050
Why?
Contract Services
1
2002
14
0.050
Why?
Financial Support
1
2002
3
0.050
Why?
Biotechnology
1
2002
12
0.050
Why?
Genetic Predisposition to Disease
1
2005
507
0.050
Why?
Health Care Sector
1
2002
15
0.050
Why?
Mice, SCID
2
2012
173
0.050
Why?
Cell Line
1
2004
1010
0.050
Why?
Drug Industry
1
2002
38
0.050
Why?
Research Support as Topic
1
2002
45
0.050
Why?
Research Subjects
1
2002
50
0.050
Why?
Neoplasm Grading
1
2021
123
0.050
Why?
Patient Selection
1
2002
254
0.040
Why?
Cooperative Behavior
1
2002
226
0.040
Why?
Intramolecular Oxidoreductases
1
2019
14
0.040
Why?
Cytoskeletal Proteins
1
2019
49
0.040
Why?
Risk Assessment
1
2023
1254
0.040
Why?
Microtubule-Associated Proteins
1
2019
65
0.040
Why?
Biomedical Research
1
2002
241
0.040
Why?
Cell Cycle Proteins
1
2019
167
0.040
Why?
Cohort Studies
1
2021
1403
0.040
Why?
Sensitivity and Specificity
1
2019
858
0.030
Why?
Caspase 3
1
2016
93
0.030
Why?
Retrospective Studies
2
2021
6124
0.030
Why?
Tissue Array Analysis
1
2015
45
0.030
Why?
Diagnosis, Differential
1
2019
1037
0.030
Why?
Epithelial-Mesenchymal Transition
1
2015
49
0.030
Why?
Prospective Studies
1
2021
2345
0.030
Why?
Exosomes
1
2015
47
0.030
Why?
HEK293 Cells
1
2015
216
0.030
Why?
Receptor, Fibroblast Growth Factor, Type 2
1
2014
11
0.030
Why?
Cell Transformation, Neoplastic
1
2015
181
0.030
Why?
Peritoneal Cavity
1
2014
8
0.030
Why?
Risk Factors
2
2014
3604
0.030
Why?
Vascular Endothelial Growth Factor A
1
2014
183
0.030
Why?
Drug Resistance, Neoplasm
1
2015
314
0.030
Why?
Disease-Free Survival
1
2014
450
0.030
Why?
MCF-7 Cells
1
2013
62
0.030
Why?
Germ-Line Mutation
1
2013
61
0.030
Why?
Homologous Recombination
1
2013
40
0.030
Why?
Amino Acid Substitution
1
2013
81
0.030
Why?
Karyotyping
1
2012
82
0.030
Why?
Extracellular Matrix Proteins
1
2013
69
0.030
Why?
Anoikis
1
2012
8
0.030
Why?
Transduction, Genetic
1
2012
45
0.030
Why?
Databases, Factual
1
2016
660
0.030
Why?
Tubulin
1
2012
20
0.030
Why?
Mice, Inbred NOD
1
2012
94
0.030
Why?
Signal Transduction
2
2011
1608
0.030
Why?
Tamoxifen
1
2012
59
0.030
Why?
DNA Fingerprinting
1
2012
62
0.030
Why?
Cell Adhesion
1
2012
155
0.030
Why?
Antibody Specificity
1
2012
35
0.030
Why?
Amino Acid Sequence
1
2013
579
0.020
Why?
Perioperative Period
1
2011
22
0.020
Why?
Tumor Suppressor Protein p53
1
2013
213
0.020
Why?
Estradiol
1
2012
213
0.020
Why?
Disease Models, Animal
1
2016
1411
0.020
Why?
Microtubules
1
2011
41
0.020
Why?
Cell Cycle Checkpoints
1
2011
30
0.020
Why?
Mitosis
1
2011
88
0.020
Why?
Gene Expression
1
2013
612
0.020
Why?
Regression Analysis
1
2011
385
0.020
Why?
HeLa Cells
1
2011
257
0.020
Why?
Disease Progression
1
2012
820
0.020
Why?
Cells, Cultured
1
2013
1587
0.020
Why?
Severity of Illness Index
1
2011
953
0.020
Why?
Progesterone Congeners
1
2008
5
0.020
Why?
Progesterone
1
2008
57
0.020
Why?
Mutation
1
2013
1292
0.020
Why?
Protein Kinases
1
2008
70
0.020
Why?
Cell Nucleus
1
2008
186
0.020
Why?
Tumor Cells, Cultured
1
2008
462
0.020
Why?
Transcriptional Activation
1
2006
121
0.020
Why?
DNA, Neoplasm
1
2006
145
0.020
Why?
Protein Structure, Tertiary
1
2006
249
0.020
Why?
Binding Sites
1
2006
378
0.020
Why?
Repressor Proteins
1
2006
149
0.020
Why?
Pregnancy
1
2011
2468
0.010
Why?
Truth Disclosure
1
2004
14
0.010
Why?
Genetic Diseases, Inborn
1
2004
21
0.010
Why?
Male
1
2011
25450
0.010
Why?
Spillman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Similar People Expand Description
_